Free
Articles  |   January 2003
A novel therapeutic approach to dyslipidemia
Article Information
Cardiovascular Disorders
Articles   |   January 2003
A novel therapeutic approach to dyslipidemia
The Journal of the American Osteopathic Association, January 2003, Vol. 103, 16S-20S. doi:https://doi.org/
The Journal of the American Osteopathic Association, January 2003, Vol. 103, 16S-20S. doi:https://doi.org/
This content is PDF only. Please click on the PDF icon to access.
Abstract

The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) guidelines call for more aggressive lowering of low-density lipoprotein cholesterol (LDL-C) and will substantially increase the number of patients eligible for lipid-lowering therapy. Statins, the current treatment standard, have proven to be highly efficacious in lowering LDL-C and reducing coronary heart disease (CHD) risk. Because some patients are unable to tolerate 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) or they are not candidates for statin therapy, however, other cholesterol-lowering modes of therapy are needed. Currently available nonstatin drugs often do not reliably reduce LDL-C to a desired extent or are limited in their safety and tolerability. Ezetimibe, a novel lipid-lowering agent until recently in phase III development, is the first in a new class of selective cholesterol absorption inhibitors and offers a promising new approach to the treatment of dyslipidemia. This article reviews the cholesterol metabolic pathways and the mechanism of action of the currently available lipid-modifying agents and introduces ezetimibe, the first selective cholesterol absorption inhibitor.